
    
      This clinical trial is an international multi-center prospective clinical registry research,
      for evaluating the efficacy and safety of Firebird 2 cobalt-chromium alloyed
      sirolimus-eluting stent in treatment of complex coronary lesions in diabetes. As planned,
      about 57 research centers all over China, Latin America and Asia-Pacific areas will be
      involved and, 1300 patients will be enrolled into this research. The implanted stents must
      all be Firebird2 cobalt-chromium alloyed sirolimus-eluting stent. The patient enrollment will
      last for 12 months. Clinical follow-up will be done respectively for 30 days, 6 months, 12
      months, 18 months, 24 months, 30 months and 36 months. All quitted patients during the study
      will not be replaced with any substitutes, but categorized in the enrollment failure column.
      The researcher must state clear the reason of nonenrollment.
    
  